Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma

Sang Eun Yoon1, Yeon Jeong Kim1, Joon Ho Shim2,3, Donghyun Park2,4, Junhun Cho5, Young Hyeok6, Woong-Yang Park2,6, Yeung-Chul Mun7, Kyoung Eun Lee8, Duck Cho9, Won Seog Kim7,8, Seek Jin Kim1,2

1Division of Hematology-oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 2Samsung Genome Institute, Samsung Medical Center, Seoul, 3Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, 4GENINUS Inc., Seoul, 5Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 6Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, 7Division of Hematology-Oncology, Department of Internal Medicine, Ewha Medical Research Center, Ewha Womans University School of Medicine, Seoul, 8Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Purpose Analysis of circulating tumor DNA (ctDNA) in blood could allow noninvasive genetic analysis of primary tumors. Although there have been unmet needs for noninvasive methods in patients with primary central nervous system lymphoma (PCNSL), it is still not determined whether plasma ctDNA analysis could be useful for patients with PCNSL.

Materials and Methods Targeted deep sequencing of 54 genes was performed in cell-free DNA isolated from plasma samples collected pretreatment, during treatment, and at the end of treatment in 42 consecutively diagnosed PCNSL patients between January 2017 and December 2018.

Results Targeted sequencing of plasma cell-free DNA detected somatic mutations representing ctDNA in 11 cases (11/41, 27%). The detection of ctDNA was not related to the concentration of cell-free DNA or tumor volume. The mutation profiles of these 11 cases varied between patients. The most frequently mutated gene was PIM1 (4/11, 36.4%), whereas KMT2D, PIK3CA, and MYD88 were each observed in three patients (3/11, 27%). The mutations of 13 genes were concordantly found in primary tumor tissue and plasma ctDNA, giving a detection sensitivity of 45%. During the serial tracking of seven patients with complete response, the disappearance of ctDNA mutations was found in four patients, whereas three patients had detected ctDNA mutation at the end of treatment.

Conclusion The plasma ctDNA mutation analysis still has limited value for surveillance and predicting treatment outcomes of PCNSL because the detection efficiency was lower than other systemic lymphomas. Thus, analytical platforms should be improved to overcome anatomical hurdles associated with PCNSL.

Key words Primary CNS lymphoma, Circulating tumor DNA, Prognosis

Introduction

Primary central nervous system lymphoma (PCNSL) is a rare subtype of non-Hodgkin lymphoma (NHL), accounting for less than 2% of all NHLs, with most cases of PCNSL having diffuse large B-cell lymphoma (DLBCL) histopathology [1]. Because of the necessity to cross the blood-brain barrier (BBB), the induction treatment regimens for PCNSL differ from those for systemic DLBCL. Thus, chemotherapy containing high-dose methotrexate (HD-MTX) is the mainstay of PCNSL treatment [2]. However, relapse remains a significant issue, and one-third of PCNSL patients become refractory to salvage treatment [3]. Although previous mutation analyses have shown mutation profiles associated with the nuclear factor-κB (NF-κB) pathway, B-cell receptor activity, and immune evasion [4,5], information about PCNSL tumor biology and therapeutic targets is limited because brain biopsy is not always possible at diagnosis or relapse due to the risk of neurologic sequelae related to this invasive procedure.

Blood-based tumor diagnosis and surveillance through noninvasive blood sampling, or so-called liquid biopsy, is a rapidly advancing field in cancer research. Blood contains circulating tumor DNA (ctDNA), which is thought to be derived from tumor tissue and/or lysed circulating tumor cells [6]. The application of next-generation sequencing (NGS) for mutation analysis has allowed ctDNA-based tumor genotyping, and high-throughput sequencing of ctDNA could serve as a surrogate for sequencing the entire tumor genome [7]. Accordingly, ctDNA-based tumor
Materials and Methods

1. Patients

We have conducted a single-center, prospective cohort study of adult patients with lymphoma since January 2017 (the Prospective Cohort Study for Lymphoma: ClinicalTrials.gov Identifier: NCT03117036). Patients admitted to our hospital for newly diagnosed or relapsed/refractory Hodgkin and NHL were eligible for this prospective cohort. Once patients were enrolled after providing written informed consent, they were treated after laboratory evaluation and monitored in a real-life context. At the same time, we collected and stored biological samples, including germline DNA, serum, and plasma cfDNA, for future research at our institute. As part of this prospective cohort study, we analyzed 42 patients with newly diagnosed PCNSL (n=39) or relapsed PCNSL (n=3) out of 751 patients enrolled between January 2017 and December 2018 (Fig. 1A). Plasma samples were collected at enrollment of the prospective cohort, after two cycles of induction chemotherapy, and at the end of treatment or at the time of progression (Fig. 1B). The tumor pathology was confirmed by two lymphoma pathologists (K.Y.H. and C.H), and all patients were evaluated for staging workup and risk stratification according to the guideline of the International Extranodal Lymphoma Study Group (IELSG), including physical examinations, complete blood cell counts, serum biochemistry, brain magnetic resonance imaging (MRI), bone marrow aspiration, ophthalmologic examination, and CSF cytology analysis. Treatment response was assessed as described by the International PCNSL Collaborative Group (IPCG) [17]. Thus, brain MRI was repeated during and after treatment to evaluate the response. For patients who achieved complete response, the follow-up evaluation with brain MRI was performed every three to four months as surveillance for relapse.

2. Sample preparation and cfDNA extraction

Whole blood samples were collected in Cell-Free DNA BCT tubes (Streck Inc., Omaha, NE). Plasma was prepared using three centrifugation steps at room temperature with increasing centrifugal force: 840 ×g for 10 minutes, 1,040 ×g for 10 minutes, and then 5,000 ×g for 10 minutes. After separation of plasma in the initial centrifugation, mononuclear cells were separated by Ficoll gradient centrifugation, and the granulocytes were purified from the pellet using Red Blood Cell lysis buffer (Qiagen, Santa Clarita, CA). Genomic DNA was isolated from the mononuclear cells using a QIAamp DNA mini kit (Qiagen). Plasma DNA was obtained from 2 to 5 mL of plasma using a QIAamp Circulating Nucleic Acid Kit (Qiagen). The AllPrep DNA/RNA Mini Kit (Qiagen) was used to purify genomic DNA (gDNA) from tissue samples. DNA concentration and purity were measured using a Qubit 2.0 Fluorometer (Life Technologies, Grand Island, NY). The fragment size distribution was measured using a 2200 TapeStation Instrument (Agilent Technologies, Santa Clara, CA).

3. Library preparation, sequencing, and data processing

Purified gDNA was sonicated (7 minutes, 0.5% power, intensity of 0.1, and 50 cycles/burst) into 150-200 bp fragments using a Covaris S2 (Covaris Inc., Woburn, MA). Tissue samples previously acquired for diagnosis were used...
to create reference libraries and were subjected to targeted sequencing. The tumor biopsy sample libraries were constructed using a SureSelect XT reagent kit, HSQ (Agilent Technologies), according to the manufacturer’s instructions. The mononuclear cell gDNA and plasma cfDNA libraries were created using a KAPA Hyper Prep Kit (Kapa Biosystems, Woburn, MA). Briefly, after end repair and A-tailing according to the manufacturer’s protocol, we performed
adapter ligation at 4°C overnight using a customized adapter with molecular barcode (Integrated Device Technology, San Jose, CA). For the construction of libraries from biopsy specimens, hybrid selection was performed using customized probes targeting 426 lymphoma-related genes. To generate ultra-deep sequencing data at an affordable cost, we selected 54 genes according to the frequency of mutations in lymphoma. Thus, when we evaluated the coverage of these 54 genes for detecting somatic mutations across B-cell lymphomas using the COSMIC lymphoma database, 81.4% (848/972) of DLBCL patients were found to carry at least one mutation within the target regions of our panel. For sequencing of cfDNA in this study, capture probes for 54 genes were customized (Fig. 1B).

From the 54 genes, we designed baits targeting 617 regions covering 117,381 bases of the human genome. Total reads generated from cfDNAs and gDNAs were 39.6 and 33.5 million reads on average. After removing duplicates, we achieved 5,914.4× and 5,900.5× mean depth for cfDNAs and gDNAs, respectively. All data were aligned to the hg19 reference using BWA mem (v. 0.7.5, Wellcome Trust Sanger Institute, Cambridge, UK). Sequence Alignment/Map Format (SAM) files were converted to Binary SAM format using Samtools (v. 1.6, Wellcome Trust Sanger Institute). In preprocessing steps, Genome Analysis Tool Kit (GATK) (v. 4.0.0, Broad Institute, Cambridge, UK) and Picard (v. 2.9.4, Broad Institute) were used for quality controls of NGS data. The base recalibration process was performed by BaseRecalibrator and ApplyBQSR function in GATK software. Picard was used to identifying UID family in each group of PCR duplicates. After identifying UID family, we applied a home-built Python (v. 2.7.9, Python Software Foundation, Wilmington, DE) scripts to process the duplicate reads. We modified integrated digital error suppression methods by Newman et al. [18] and made scripts to perform the method, which combined in silico elimination of stereotypical background errors with a molecular barcoding strategy for the sensitive detection of ctDNA [19,20]. The parallel sequencing of matched

| Characteristic                      | Total |  |  |  |  |
|------------------------------------|------|---|---|---|---|
| No. of patients                    | 42   | 22 (52.4) | 20 (47.6) | 22 (52.4) | 20 (47.6) |
| Sex                                |      | 11 (26.2) | 7 (36.4) | 15 (48.4) | 16 (51.6) |
| Age (yr)                           |      | 1 (9.1) | 4 (36.4) | 7 (63.6) | 4 (36.4) |
| ECOG PS                            |      | 1 (9.1) | 1 (9.1) | 7 (63.6) | 7 (63.6) |
| LDH                                |      | 3 (2.3) | 5 (11.9) | 8 (72.7) | 5 (11.9) |
| CSF                                |      | 1 (2.4) | 11 (26.2) | 8 (61.9) | 5 (11.9) |
| IELSG                              |      | 0 | 1 (3.2) | 1 (9.0) | 1 (3.2) |
| Treatment                          |      | 2 (18.2) | 3 (27.3) | 2 (18.2) | 3 (27.3) |
| Chemotherapy followed by ASCT      |      | 4 (12.9) | 5 (16.1) | 5 (16.1) | 5 (16.1) |
| Chemotherapy plus cytarabine consol |      | 4 (12.9) | 5 (16.1) | 5 (16.1) | 5 (16.1) |
| Chemotherapy plus by whole-brain r |      | 6 (14.3) | 2 (18.2) | 4 (12.9) | 2 (18.2) |
| Circulating tumor DNA              |      | 11 (26.2) | 7 (36.4) | 15 (48.4) | 16 (51.6) |
| Detected                           |      | 11 (26.2) | 7 (36.4) | 15 (48.4) | 16 (51.6) |
| Not detected                       |      | 31 (73.8) | 16 (51.6) | 31 (73.8) | 31 (73.8) |
| p-value                            |      | 0.49 | 0.49 | 0.49 | 0.49 |

Values are presented as number (%). ASCT, autologous stem cell transplantation; CSF, cerebrospinal fluid; ECOG PS, Eastern Oncology Cooperative Group performance status; IELSG, International Extranodal Lymphoma Study Group; LDH, lactate dehydrogenase.
white blood cells was performed to exclude mutations associated with clonal hematopoiesis and enable appropriate variant calling. During the processing, discordant pairs and off-target reads were filtered out. The variants that passed through the germline filter were designated as somatic mutations, and the filtering steps and sequencing metrics were summarized in Supplementary Methods and S1 Table [21]. The quantitative levels of ctDNA were measured as genome equivalents (GE) that were determined as the product of total cfDNA concentration and the maximal variant
allele fraction (VAF) of somatic mutations.

4. Statistical analysis
The correlations between tumor burden and DNA concentration were calculated using the Pearson correlation coefficient, and the difference of cfDNA concentrations was compared by the Wilcoxon rank-sum test. Descriptive statistics were determined as proportions and medians, and the intergroup comparisons for categorical variables were assessed by Fisher’s exact test. Progression-free survival (PFS) was calculated as the date from diagnosis to disease progression or death related to any cause. Time to progression (TTP) was also calculated as the date from diagnosis to disease progression. Overall survival (OS) was defined as the period from the date of diagnosis to death or the last date of follow-up. Survival curves were described using Kaplan-Meier estimates and were compared between groups using the log-rank test. Statistical analyses were performed using an IBM PASW ver. 24.0 software program (IBM Corp., Armonk, NY).

Results

1. Patient characteristics
Of the 42 patients with PCNSL, 40 were diagnosed with PCNSL by stereotactic biopsy (n=5), navigation biopsy (n=25), or craniectomy (n=10), and the pathology of all tumors was DLBCL. Although the remaining two patients were diagnosed by brain MRI due to the deep location of the lesion within the brain parenchyma, their complete response to HD-MTX containing chemotherapy and their CSF findings suggestive of lymphoma cells supported the diagnosis of PCNSL. The patients’ median age was 52 years (range, 19 to 85 years), and the male (n=22) to female (n=20) ratio was approximately 1:1. The CSF analysis via lumbar puncture identified the presence of tumor cells in seven patients, and ophthalmologic examination identified one patient with intravitreal involvement. Based on the unfavorable features of the IELSG (age > 60 years, Eastern Oncology Cooperative Group performance ≥ 2, elevated serum lactate dehydrogenase...
nase, elevated serum protein level, and involvement of deep brain structures including periventricular regions, basal ganglia, corpus callosum, brain stem, and cerebellum), more than half the patients (n=25) had 2-3 unfavorable features and were classified as within the intermediate-risk group (Table 1). All patients with newly diagnosed PCNSL (n=39) were uniformly treated with rituximab, HD-MTX, vincristine, and procarbazine as an induction treatment after diagnosis, and the remaining three patients who relapsed after HD-MTX–containing chemotherapy received ifosfamide, carboplatin, and dexamethasone as salvage chemotherapy. As a consolidation treatment, autologous stem cell transplantation (n=8), high-dose cytarabine chemotherapy (n=18), or whole-brain radiotherapy (n=10) were performed (Table 1). During the follow-up, eight patients died because of disease progression (Fig. 2A).

2. Analysis of plasma cfDNA
The median cfDNA concentration in the 42 patients was 13.5 ng/mL (range, 2.6 to 121.6 ng/mL), which was significantly lower than the previously reported level in patients with systemic DLBCL (median, 25.5 ng/mL; range, 4.8 to 427.6 ng/mL; p < 0.001) (Fig. 2B) [21]. The concentration of cfDNA was not significantly related to the tumor volume as estimated by the long axis of the tumor mass on brain MRI (r=0.02, p=0.90) (Fig. 2C). The involvement of deep brain structures such as periventricular regions, basal ganglia, brainstem, and cerebellum was not associated with the concentration of cfDNA (p=0.439) (Fig. 2D). Hence, when we dichotomized patients into low- and high-cfDNA based on the median concentration of cfDNA, the pretreatment concentration of cfDNA was not significantly associated with the TTP (S2A Fig.), PFS, and OS (Fig. 2E and F). Likewise,
serial changes in cfDNA did not show any significant association with the treatment outcome or disease relapse (Fig. 2G).

3. Targeted sequencing and mutation profiles of cfDNA

Targeted sequencing could be performed on the cfDNA samples of 41 of 42 enrolled patients, the exception being one patient with relapsed PCNSL whose isolated DNA was of poor quality. Somatic mutations within the target genes were detected in 11 patients (11/41, 27%) but not in the remaining 30. The median concentration of cfDNA in the 11 patients in whom a mutation was detected was not significantly different from that in the remaining 30 patients (p=0.061) (Fig. 3A). The detection of a mutation was not related to the concentration of cfDNA within the poor-risk groups of IELSG, whereas the concentration of cfDNA was higher in 18 patients who did not show mutations than patients whose mutation was detected (Fig. 3B). Out of 42 patients, dexamethasone was empirically administered in 33 patients prior to the induction chemotherapy. However, the use of dexamethasone...
Fig. 4. Pretreatment mutations detected by plasma circulating tumor DNA (ctDNA) and treatment outcomes. (A) A patient (P596) with a high number of mutations at diagnosis experienced early progression during treatment. (B) A patient (P764) with mutations of plasma ctDNA at pretreatment showed disease progression within 10 months after the end of treatment. (C) The summary of 11 patients’ progression-free survival and plasma ctDNA mutation burden at diagnosis.
Fig. 5. Serial monitoring of mutation profiles of plasma circulating tumor DNA (ctDNA) in primary central nervous system lymphoma (PCNSL). The ctDNA diversity and levels assessed by targeted deep sequencing are indicated on the y-axis. The time course of diagnosis, interim, and final analysis are indicated on the x-axis. The therapeutic response of patients at the time of analysis was estimated from their International PCNSL Collaborative Group (IPCG). (A) Four patients showing the complete disappearance of ctDNA mutations at the final response evaluation achieved complete response at the end of treatment and maintained their response without any evidence of relapse (P205, P543, P582, and P586). However, one patient obtaining a complete response with a detected DNMT3A mutation at the end of treatment eventually relapsed during follow-up (P297). CR, complete response; PD, progressive disease; PR, partial response. (Continued to the next page)
did not influence the amount of cfDNA and detection of ctDNA mutation (data not shown). The comparison of survival outcomes between patients with and without detected mutations showed no significant difference in TTP (S2B Fig.), PFS, and OS (Fig. 3C and D). Similarly, there was no significant association of maximum GE with tumor volume in the 11 cases where ctDNA mutation was detected (r=0.210, p=0.450) (Fig. 3E). Mutation profiles of these 11 cases varied from one to multiple somatic mutations per patient (Fig. 3F). Of the genes in which mutations were detected, PIM1 mutation was the most frequently found (4/11, 36.4%), and the mutations of KMT2D, PIK3CA, and MYD88 were each observed in three patients (3/11, 27%). Mutations of BTG1, CARD11, DNMT3A, IRF4, PIK3CD, PRDM1, and STAT6 were each found in two patients, whereas mutations of BCOR, BTG2, CXC4, DUSP2, DUSP22, HIST1H1C, PAX5, TBL1XR1, TET2, TNFRSF14, and TP53 were each detected in only one patient (Fig. 3F). The VAF of these mutations in plasma ctDNA varied between patients: the majority of patients showed low VAF for each gene, with three exceptions (Fig. 3F): P596 (PIM1, MYD88, BTG1, and BTG2), P152 (PIK3CA), and P582 (CCND3, MYD88). In addition, the VAFs of KMT2D, PRDM1, IRF4, and STAT6 were much lower than those of other genes. Next, we compared the mutation profiles identified in plasma ctDNA with those of tumor tissue. In the five patients with tumor tissue samples available for targeted sequencing, the mutation profiles of the primary tumor showed a higher number of somatic mutations than the mutation profiles of plasma ctDNA (n=29 vs. n=13) (Fig. 3G). Of these 29 somatic mutations, 13 were concordantly detected in plasma ctDNA, giving a detection sensitivity of 45%. The median VAF of plasma ctDNA mutations (4.3%; range, 0.5% to 51.2%) was also lower than that of tumor tissue (25.1%; range, 2.3% to 64.7%).

4. Association of plasma ctDNA mutation profiles with treatment outcome

One patient harboring pretreatment plasma ctDNA multiple mutations, including MYD88, PIM1, BTG1, and BTG2, experienced early progression resulting in death (P596) (Fig. 4A). On the other hand, the other patient with multiple mutations involving KMT2D, STAT6, CARD11, and PAX5 was alive even after relapse (P764) (Fig. 4B). When survival outcomes of 11 patients whose ctDNA mutations were detected at diagnosis were compared, there was no significant association between high plasma ctDNA mutation burden and poor survival (Fig. 4C). However, patients with relatively low plasma ctDNA mutation burden seemed to be
Fig. 5. (Continued from the previous page) (B) Three patients (P152, P309, and P223) who achieved a complete response assessed by brain magnetic resonance imaging showed the persistence of mutations in plasma ctDNA after treatment. One patient showed a new mutation in the interim analysis but did not show any evidence of relapse at the time of analysis (P152), and another patient receiving hemodialysis showed the persistence of mutations (P309). The other patient harboring a persistent TET2 mutation at the interim and end of treatment analyses showed a late relapse during follow-up (P223). (Continued to the next page)
Discussion

In this study, we investigated the clinical relevance of plasma ctDNA-based mutation analysis in 42 patients who were consecutively enrolled in our prospective cohort. Considering that the feasibility of blood-based genotyping is unclear in patients with a brain tumor because of the BBB, we first measured the concentration of cfDNA in the blood of patients with PCNSL and analyzed its role as a biomarker for predicting tumor burden and treatment outcome. We observed that the concentration of cfDNA in PCNSL patients was much lower than that in patients with systemic DLBCL (Fig. 2B). Furthermore, tumor volume and tumor location were not associated with the concentration of cfDNA (Fig. 2C and D). Hence, the pretreatment cfDNA concentration and the serial changes in concentration during treatment failed to predict the treatment outcomes (Fig. 2E-G). These findings implied a lack of clinical usefulness of cfDNA concentration as a liquid biopsy-driven biomarker in patients with PCNSL.

However, plasma ctDNA-based mutation analysis detected somatic mutations in genes including KMT2D, PIK3CA, PIM 1, BTG1, CARD11, DNMT3A, IRF4, MYD88, PIK3CD, PRDM1, and STAT6, and these mutations were consistent with those identified in a previous study reporting the detection of somatic mutations related to NF-κB activation (MYD88, PIM1, IRF4, CARD11, PRDM1), apoptosis (GNA13, TP53, CDKN2A, BCL2) and B-cell receptor signaling (CD79B, ITPKB) in ctDNA of PCNSL [22]. In our study, patients having a low pretreatment plasma ctDNA mutation burden maintained their remission status (P205, P543, P586) (Fig. 4C), and patients with the disappearance of somatic mutations that were initially found in the pretreatment sample were also alive without any evidence of relapse (P205, P543, P582, P586) (Fig. 5A). Furthermore, one patient with the persistence of detected ctDNA mutation eventually relapsed (P297) (Fig. 5A). These findings might suggest the potential role of ctDNA mutations in blood for monitoring disease status and predicting relapse of patients with PCNSL. However, the number of patients whose mutations were detected was too small to draw a robust conclusion. Actually, the other patients with persistently detected ctDNA mutations maintained their response regardless of ctDNA mutations (P152 and P309) (Fig. 5B). Among them, one patient who received hemodialysis because of chronic renal failure showed persistence of a somatic mutation in plasma ctDNA even after the achievement of complete response (P309) (Fig. 5B). Although this could not be fully explained, it could be associated with impaired clearance related to renal failure because a previous study suggested that the detection of ctDNA in urine could reflect the loss of ctDNA from the kidney [23]. Another case showed a persistently detectable TET2 muta-
In conclusion, we conducted the first study to investigate the feasibility of plasma ctDNA-based mutation analysis in prospectively enrolled patients with PCNSL. Although some patients achieving complete response showed the disappearance of plasma ctDNA mutations after treatment, the number of patients was too small to draw a conclusion regarding its usefulness. Considering the low sensitivity to detect mutations in our results, the clinical application of plasma ctDNA-based mutation analysis has limitations for surveillance and predicting treatment outcomes of PCNSL. The efficacy of analytical platforms should be improved to overcome current hurdles associated with the application of plasma ctDNA analysis for patients with PCNSL.

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (https://www.e-crt.org).
Ethical Statement
The institutional review board approved the present study, and all the methods were carried out following the approved guidelines study (IRB number 2016-11-040). The written informed consent was obtained from each patient prior to study enrollment. It was conducted in accordance with the ethical principles of the Declaration of Helsinki and the Korea Good Clinical Practice. The last update of survival and disease status was done in June 2021.

Author Contributions
Conceived and designed the analysis: Yoon SE, Mun YC, Lee KE, Kim WS, Kim SJ.
Collected the data: Yoon SE, Kim YJ, Cho J, Ko YH, Cho D, Kim SJ.
Contributed data or analysis tools: Yoon SE, Kim YJ, Shim JH, Park D, Cho J, Ko YH, Park WY, Cho D, Kim WS, Kim SJ.
Performed the analysis: Yoon SE, Kim YJ, Park D, Park WY, Kim SJ.
Wrote the paper: Yoon SE, Kim YJ, Kim SJ.

Conflicts of Interest
Conflict of interest relevant to this article was not reported.

Acknowledgments
This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HR20C0025), and National Research Foundation of Korea (NRF) grants funded by the Korean Government (2021R1A2C1007531).

References

1. Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol. 2017;35:2410-8.
2. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036-47.
3. Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Ruda R, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16:e322-32.
4. Vater I, Montesinos-Rongen M, Schlesner M, Haake A, Puschke F, Sprute R, et al. The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing. Leukemia. 2015;29:677-85.
5. Zhou Y, Liu W, Xu Z, Zhu H, Xiao D, Su W, et al. Analysis of genomic alteration in primary central nervous system lymphoma and the expression of some related genes. Neoplasia. 2018;20:1059-69.
6. Jen J, Wu L, Sidransky D. An overview on the isolation and analysis of circulating tumor DNA in plasma and serum. Ann N Y Acad Sci. 2000;906:8-12.
7. Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883-92.
8. Weaver KD, Grossman SA, Herman JG. Methylated tumor-specific DNA as a plasma biomarker in patients with glioma. Cancer Invest. 2006;24:35-40.
9. Liu BL, Cheng JX, Zhang W, Zhang X, Wang R, Lin H, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol. 2010;12:540-8.
10. Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T. Liquid biopsies in patients with diffuse glioma. Acta Neuropathol. 2015;129:849-65.
11. Betsegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
12. Hickmann AK, Frick M, Hadaschik D, Battke F, Bittl M, Ganslandt O, et al. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas. BMC Cancer. 2019;19:192.
13. Rossi D, Spina V, Bruscaggin A, Gaidano G. Liquid biopsy in lymphoma. Haematologica. 2019;104:648-52.
14. Hattori K, Sakata-Yanagimoto M, Suehara Y, Yokoyama Y, Kato T, Kurita N, et al. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2018;109:225-30.
15. Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021;106:513-21.
16. Wang X, Gao Y, Shan C, Lai M, He H, Bai B, et al. Association of circulating tumor DNA from the cerebrospinal fluid with high-risk CNS involvement in patients with diffuse large B-cell lymphoma. Clin Transl Med. 2021;11:e236.
17. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulzynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034-43.
18. Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34:547-55.
19. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapRe-
duce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297-303.
20. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics. 2011;27:2987-93.
21. Shin SH, Kim YJ, Lee D, Cho D, Ko YH, Cho J, et al. Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes. Leuk Lymphoma. 2019;60:2237-46.
22. Fontanilles M, Marguet F, Bohers E, Vialilly PJ, Bertrand P, Dubois S, et al. Somatic mutations detected in plasma cell-free DNA by targeted sequencing: assessment of liquid biopsy in primary central nervous system lymphoma. Blood. 2015;126:332.
23. Watanabe J, Natsumeda M, Kanemaru Y, Okada M, Oishi M, Kakita A, et al. Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma. Leuk Lymphoma. 2019;60:3587-9.
24. Asmar F, Punj V, Christensen J, Pedersen MT, Pedersen A, Nielsen AB, et al. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica. 2013;98:1912-20.
25. Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171:481-94.
26. Kubuki Y, Yamaji T, Hidaka T, Kameda T, Shide K, Sekine M, et al. TET2 mutation in diffuse large B-cell lymphoma. J Clin Exp Hematop. 2017;56:145-9.
27. Dominguez PM, Ghamlouch H, Rosikiewicz W, Kumar P, Beguelin W, Fontan L, et al. TET2 deficiency causes germinal center hyperplasia, impairs plasma cell differentiation, and promotes B-cell lymphomagenesis. Cancer Discov. 2018;8:1632-53.
28. Fontanilles M, Marguet F, Bohers E, Vialilly PJ, Dubois S, Bertrand P, et al. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma. Oncotarget. 2017;8:48157-68.